Omnicell Announces First Quarter 2012 Results

May 02, 2012

MOUNTAIN VIEW, Calif.

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced results for its quarter ended March 31, 2012.

GAAP results: Revenue for the first quarter of 2012 was $64.1 million as compared with $62.9 million for the fourth quarter of 2011 and up $6.9 million or 12.2% from first quarter 2011 revenue of $57.2 million.

Net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $2.4 million, or $0.07 per diluted share for the first quarter of 2012, as compared with $4.1 million, or $0.12 per diluted share, for the fourth quarter of 2011 and $0.7 million, or $0.02 per diluted share, for the first quarter of 2011.

Non-GAAP results: Non-GAAP net income was $4.6 million for the first quarter of 2012, or $0.13 per diluted share, which excludes $2.2 million in stock compensation expense. This compares to non-GAAP net income of $6.4 million, or $0.19 per diluted share, for the fourth quarter of 2011, which excludes $2.2 million in stock compensation expense.  First quarter 2012 results compare to non-GAAP net income of $3.7 million or $0.11 per diluted share, for the first quarter of 2011, which excludes $2.4 million in stock compensation expense and $1.0 million pre-tax settlement expense for litigation claims, net of a $0.4 million tax effect.

"I am pleased with our performance and results in the first quarter of 2012," said Randall Lipps, Omnicell President, Chairman and CEO. "The solid results of the quarter keep our momentum in line with our annual growth projections in both revenue and profit.”

To continue reading this article and to review the financial tables, please click here.